Tetrandrine alleviates silicosis by inhibiting canonical and non-canonical NLRP3 inflammasome activation in lung macrophages

Mei-yue Song1,2,3, Jia-xin Wang4, You-liang Sun5, Zhi-fa Han6, Yi-tian Zhou7,8,9, Ying Liu7, Tian-hui Fan7, Zhao-guo Li10, Xian-mei Qi7, Ya Luo7, Pei-ran Yang7, Bai-cun Li7, Xin-ri Zhang1,2, Jing Wang7 and Chen Wang7

Silicosis caused by inhalation of silica particles leads to more than ten thousand new occupational exposure-related deaths yearly. Exacerbating this issue, there are currently few drugs reported to effectively treat silicosis. Tetrandrine is the only drug approved for silicosis treatment in China, and despite more than decades of use, its efficacy and mechanisms of action remain largely unknown. Here, in this study, we established silicosis mouse models to investigate the effectiveness of tetrandrine of early and late therapeutic administration. To this end, we used multiple cardiopulmonary function test, as well as markers for inflammation and fibrosis. Moreover, using single cell RNA sequencing and transcriptomics of lung tissue and quantitative microarray analysis of serum from silicosis and control mice, our results provide a novel description of the target pathways for tetrandrine. Specifically, we found that tetrandrine attenuated silicosis by inhibiting both the canonical and non-canonical NLRP3 inflammasome pathways in lung macrophages. Taken together, our work showed that tetrandrine yielded promising results against silicosis-associated inflammation and fibrosis and further lied the groundwork for understanding its molecular targets. Our results also facilitated the wider adoption and development of tetrandrine, potentially accelerating a globally accepted therapeutic strategy for silicosis.

Key words: tetrandrine; silicosis; macrophages; NLRP3 inflammasome; lung function

INTRODUCTION
Silicosis is an interstitial lung disease caused by the inhalation of crystalline silica particles and characterized by acute and chronic inflammation with subsequent diffuse fibrosis leading to progressive respiratory insufficiency [1]. It is currently one of the most dangerous occupational diseases worldwide, and responsible for an estimated 10,000 or more new deaths every year [2]. Although protective measures such as dust control and respirators have been applied in attempts to reduce silicosis-associated morbidity, new outbreaks still occur where mining and industrial use of silica materials are prevalent [2]. Unfortunately, aside from lung transplantation, few advances have been made to date in the development of viable treatment options [3]. In China, tetrandrine (Tet) has been approved to treat silicosis although the mechanism of its activity is still largely unclear. Therefore, study of the mechanisms of Tet against silicosis is highly relevant to increasing its effective application and further development of other anti-silicosis candidate drugs.
The NLRP3 (NLR family pyrin domain-containing 3) inflamma-
some has been established as a major proinflammatory receptor
for sensing environmental danger, such as crystalline silica, and
subsequently initiating proinflammatory events during the pro-
gression of silicosis [9, 10]. Upon NLRP3 inflammasome activation
by crystalline silica, macrophages secrete increasing levels of the
proinflammatory factor interleukin (IL)-1β, downstream of the
NLRP3 inflammasome. Notably, research in silica-induced animal
models has firmly demonstrated that IL-1β secretion exacerbates
silicosis, whereas its neutralization can reverse this disease [11, 12].
More importantly, a case report documented that IL-1 receptor
blockade dampened the pulmonary inflammation and impeded
the progressive deteriorations of respiratory function in silicosis
patients [13]. Moreover, multiple studies have reported that
Tet has the strong potential to inhibit the release of inflammatory
cytokines [5, 14], especially IL-1β [7], which greatly contributes
to the pathogenesis of silicosis. Given the sound inhibitory
effects of Tet against IL-1β, it is reasonable to speculate that the
effectiveness of Tet treatment against silicosis is likely
mediated by suppressing activation of the NLRP3 inflammasome.
However, the precise genetic or molecular basis by which Tet
targets NLRP3 inflammasome signaling pathways requires thor-
ough investigation.

In this work, we employed multiple experimental approaches to
assess the early and late therapeutic effectiveness of Tet in silicosis
mouse models. In particular, we examined the effects of these
treatment regimens on cardiopulmonary function, inflammation,
and fibrosis, and confirmed that Tet exerted credible, therapeutic
effects on silicosis. In addition, we combined single cell RNAseq and
transcriptomics strategies of murine lung tissue to identify the
canonical and non-canonical NLRP3 inflammasome signal cascades
in pulmonary macrophages as downstream targets of Tet to
suppress silicosis-associated inflammation and fibrosis, both
in vivo and in vitro. Our study provides a much necessary theoretical
framework for understanding how Tet acts in suppression of silicosis
and suggests combined therapeutic approaches for improving Tet
effectiveness in the clinic.

MATERIALS AND METHODS
Reagents
Crystalline silica particles with mass median diameter less than
1.6 µm were obtained from Forsman Scientific (Beijing) Co., Ltd
(CAS: 7631-86-9; purity 99%). These particles were endotoxin-free
by baking at 180 °C for at least 2 h and then suspended in the
sterile phosphate buffer saline (PBS). All silica suspension was
sonicated for at least 15 min and vortexed for 1 min prior to use.
Tet with purity higher than 98% was purchased from the Dibo
sonicated for at least 15 min and vortexed for 1 min prior to use.
Sodium. The suspension of Tet was then diluted in Dulbecco’s
Medium (DMEM). Suspensions of Tet were treated with indicated agents and incubated for 3 h. Cells
and cell supernatant were collected and then assayed.

Lung function test
Lung function test was performed using FlexiVent apparatus with
the forced oscillation system (SCI REQ, Montreal, Quebec, Canada)
following the manufacturer’s protocol. Briefly, after tracheotomy,
tracheas of all deeply anesthetized mice were connected with an
auto-ventilator by an endotracheal tube. Then, resistance (Rs),
compliance (Cs), and elastance (Es) of the whole respiratory
system (lung, airways and chest wall) were obtained under
“snapshot perturbation” maneuver, tissue damping (resistance) G
and H under forced oscillation perturbation (primewave-8)
maneuver, static compliance (Cst) and inspiratory capacity (IC)
under maximal PV loops maneuver. All maneuvers and perturba-
tions were conducted until numerical stability and two values
were achieved.

Cell culture
Murine peritoneal macrophages were extracted from peritoneal
lavage fluid of C57BL/6J mice following intraperitoneal injection of
3% thiglycolate for 72 h. The peritoneal macrophages were cultured in DMEM supplemented with 10% fetal bovine serum
(FBS) and 1% penicillin and streptomycin at 37 °C under 5% CO2.

Silicosis model and Tet administration
The silicosis model was established by a single intratracheal
exposure of silica suspension as previously delineation [15]. Briefly,
mice were anesthetized with 2% pentobarbital (i.p., 0.2 mL/100 g,
Sigma-Aldrich) and then 20 µL silica suspension (600 mg of silica
in 1 mL of sterile PBS) was delivered into trachea for each mouse.
Mice in the sham groups were treated intratracheally with an
equal volume of PBS.

To establish an early therapeutic model of Tet administration,
mice were randomly divided into five groups (5 mice per group):
PBS control group, in which the mice were intratracheally
instilled with PBS and gavage administered vehicle (1% CMC-Na)
only; PBS + Tet group, in which the mice were intratracheally
instilled with PBS and gavage administered Tet (100 mg/kg);
silica control group, in which the mice were instilled with silica
and gavage administered vehicle (1% CMC-Na) only; silica + LT/
HT group, in which the mice were intratracheally instilled with
silica and gavage administered low dose (50 mg/kg) or high
dose (100 mg/kg) of Tet. These mice in treatment groups
were subjected to silica and simultaneously treated with Tet for
4 weeks. For late therapeutic experiments, mice were divided
into four groups (9 mice per group): PBS, PBS + Tet, silica, and
silica + Tet (100 mg/kg) groups, in which the mice were treated
same as their counterparts in the early therapeutic model.

In this work, we employed multiple experimental approaches to
assess the early and late therapeutic effectiveness of Tet in silicosis
mouse models. In particular, we examined the effects of these
treatment regimens on cardiopulmonary function, inflammation,
and fibrosis, and confirmed that Tet exerted credible, therapeutic
effects on silicosis. In addition, we combined single cell RNAseq and
transcriptomics strategies of murine lung tissue to identify the
canonical and non-canonical NLRP3 inflammasome signal cascades
in pulmonary macrophages as downstream targets of Tet to
suppress silicosis-associated inflammation and fibrosis, both
in vivo and in vitro. Our study provides a much necessary theoretical
framework for understanding how Tet acts in suppression of silicosis
and suggests combined therapeutic approaches for improving Tet
effectiveness in the clinic.
Bronchoalveolar lavage fluid collection
Bronchoalveolar lavage fluid (BALF) was obtained as previously reported [15]. In brief, after the right bronchus was clamped, the left lung lobe was lavaged with 0.4 mL of 0.9% NaCl for three times to recover the BALF. The samples were subsequently placed on ice and were processed within 2 h. Samples were centrifuged at 800 r/min for 5 min at 4 °C and the supernatant was stored at −80 °C until analysis. The deposited cells were washed and re-suspended with 300 μL of cold PBS for differential cell population count by Grunewald-Giemsa staining and total cell count by automatic cell counter.

Histological analysis
The left lung samples were fixed into 4% paraformaldehyde and then embedded in paraffin. Sample blocks were sectioned (5 μM per section) for Hematoxylin and eosin (HE) staining to evaluate inflammation by Szapiei’s method [17], Masson’s trichrome staining to assess the fibrotic degree according to King’s method [18]. All sections after staining were visualized using 3D HISTECH digital slice scanner (Hungary). The assessment of fibrotic lesions was determined by Fibrotic Lesion Scores that applied as previously described [15]. In detail, distinct silicotic nodules were classified according to King’s method and different weight ranging 0-5 was determined. Then Fibrotic Lesion Score was calculated as the weight levels (0-5) multiplied by their corresponding percentage of fibrotic area over the total area of the tissue section. For immunohistochemistry (IHC), murine lung sections were stained with the anti-collagen-I antibody (1/200 dilution) at 4 °C overnight, then washed and incubated with secondary antibody for 1 h at room temperature. Sirius Red staining was performed by incubating slides in 0.1% Sirius Red F3B for 1 h, washing twice in acidified water, dehydrating thrice in 100% ethanol, and then clearing in xylene. The percentage of positive stained areas by IHC and Sirius Red staining was blindly determined by two pathologists and reported as percentage.

Hydroxyproline assay
The measurement of hydroxyproline was detected with a hydroxyproline (HYP) measurement kit (NB2P-59747, Novus Biologicals, Littleton, CO, USA) rigorously based on the manufacturer’s instructions. Approximately 20 mg (wet weight) lung tissue of each mouse was collected to detect. The absorbance of 560 nm was measured and the hydroxyproline content was determined against standards of HYP.

Quantitative PCR
According to the manufacturer’s instructions, total RNA from lung tissue or cell samples was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Complementary DNA (cDNA) was synthesized by reverse transcription with a Tiangen kit (KR103, Tiangen Biotechnology, Beijing, China). Gene expression was analyzed by quantitative PCR assay. The PCR amplification was performed in triplicate using SYBR Green I Q-PCR kit (TransGen Biotech, Beijing, China). Data acquisition and analysis of quantitative PCR assay were conducted in a Bio-Rad IQ5 system (Bio-Rad, Hercules, CA, USA). To normalize non-PCR-related fluorescence fluctuations between wells, each fluorescent reporter signal was detected against the internal reference dye signal of β-Actin. Sequences of primers used in our experiment were listed in Supplementary Table1. All primers were synthesized by Beijing Tianyihuiyuan Biotechnology Company.

Western blot
The total protein was extracted with RIPA lysis buffer from lung tissue (P0013B, Beyotime, Shanghai, China). Protein concentration of samples was detected using BCA Protein Assay Kit (23225, Thermo Fisher Scientific, Waltham, MA, USA). Protein samples were separated on an 8%-15% SDS-polyacrylamide gel electrophoresis gel and transferred onto polyvinylidene difluoride (PVDF) membranes. Tanon Automatic Chemiluminescence/Fluorescence Image Analysis System (5200, Tanon, Shanghai, China) was used for protein signal detection. Protein relative expression level was analyzed by ImageJ software and calculated as: band gray value/ internal parameter (Actin) gray value. Antibodies are described in the supplementary materials.

ELISA and Quantitative inflammatory microarray
The protein levels of IL-1β and IL-18 in BALF and serum, as well as IL-6 in BALF were detected by ELISA kits according to the manufacturer’s instructions. Specific kits information was listed in the supplementary materials.

The profiles of 308 cytokines in serum of mice in blank PBS group, silica group and silica + Tet group were simultaneously detected using a mouse L308 quantitative microarray (AAM-BlG-1-4, RayBiotech, Guangzhou, China) according to the manufacturer’s instructions. The cytokines with significantly distinct expression were screened out and analyzed.

RNA sequencing
RNA sequencing (RNA-seq) was conducted using lung tissues from PBS mice (n = 3), silicosis mice (n = 3) and Tet-administered silicosis mice in late therapeutic administration model (n = 3). Paired-end reads of 150 bp length were generated using Illumina Hiseq platform. Cleaned reads were obtained by excluding adaptors and lower quality reads, and were then mapped to Ensmbil GRCm38 mouse reference genome by Hisat2 (v.2.1.0) with specifying option “−dta”. Samtools (v.1.9) was used to sort mapped reads and transform decimal sam files to binary bam files. Sorted reads were assigned to Ensmbil GRCm38.90 mouse annotated genomes by Stringtie (v.2.0) with specifying parameter “-e”. Gene expression of matrix was analyzed by python script prepDE.py. Normalization and gene differential expression were analyzed by R package DESeq2 (v.3.10). The differentially expressed genes were obtained within PBS group versus silicosis group and silicosis group versus Tet-administered group, respectively.

Single cell RNA sequencing
Four samples from PBS control and three samples from silica models (treated with silica for 6 weeks) were used for single cell RNA-seq using 10xGenomics platform. Cell Ranger (v3.0.2) software from 10X genomics and scrublet Python package were hired to perform read alignment and quality control. The samples were integrated and clustered using Seurat R package (v3.1.4). Approximately 51,000 single cells passed QC and annotated to 18 distinct clusters based on gene expression patterns of each cell.

Statistical analysis
All statistics were performed using Prism 8.0 software. For all the graphs, data were represented as mean ± SEM (standard error of the mean), P value < 0.05 was considered statistically significant. Before analysis, normality tests were conducted for all data. Comparisons between multiple groups were carried out using two-ways ANOVA followed by Tukey post hoc-test. Nonparametric tests were applied to data that were not normally distributed.

RESULTS
Tet treatment improved lung impairment, inflammation, and fibrosis in an early therapeutic silicosis mouse model
In order to evaluate the effects of Tet administration systematically and comprehensively prior to silicotic fibrosis we examined lung function, inflammatory response, and fibrosis development in a silicosis mouse model treated with Tet. To establish the silicosis mouse model, we applied a single intratracheal instillation of silica suspension in 8-week-old male C57BL/6 J mice. At the time of silica instillation, mice were also given intra gastric Tet for 4 weeks until sacrifice (Fig. 1a). Mice were evaluated prior to sacrifice. We
found that, compared with untreated controls, high-dose Tet administration, which is superior to low-dose Tet, resulted in attenuation of silica-induced impairment of lung function, based on several indicators including inspiratory capacity (IC) (Fig. 1b), static compliance of the respirable system (Cst) (Fig. 1c), tissue damping (resistance) G (Fig. 1d), H (Fig. 1e), compliance (Crs) (Fig. S1a). However, both low- and high-dose Tet both reduced elastance (Ers) (Fig. S1b), and only low-dose Tet exhibited...
Tetrandrine inhibits NLRP3 inflammasome pathway in silicosis macrophages
MY Song et al.

good outcome on resistance (Rs) (Fig. S1c) of the respirable system. Previous studies showed that silicosis could dramatically increase the risk of pulmonary hypertension in patients and mice [19–21]. Thus, we evaluated right ventricular systolic pressure (RVSP) (Fig. 1f) and right ventricular hypertrophy index (RVHI) (Fig. S1d) and found RVSP was reduced in high dose of Tet-treated silicosis mice, whereas RVHI exhibited a decreasing trend with no statistical significance.

Immune cells, especially macrophages associated with lung inflammation were also remarkably increased in untreated silicosis mice compared with the PBS control group, as indicated by higher macrophages (Fig. 1g), lymphocytes (Fig. S1e), neutrophils (Fig. S1f), and total cell count (Fig. S1h) in bronchoalveolar lavage fluid (BALF). Among them, macrophages count in BALF was reduced by Tet treatment. Furthermore, hematoyxin and eosin (HE) staining (Fig. 1h, i) of lung sections indicated more severe diffuse alveolitis in the silicosis group than in the Tet-treatment group. Likewise, mRNA and protein levels of IL-1β (Fig. 1k, m) and IL-6 (Fig. 1l, n) were both down-regulated under Tet treatment. We next examined the level of pulmonary fibrosis between silicosis and Tet-treated lungs using several tissue staining techniques. Masson’s trichrome staining (Fig. 1h, j) revealed a less degree of collagen deposition in the Tet-treated silicosis lungs than in the silicosis lungs. Similarly, collagen-I staining by both Sirius Red (Fig. S1g, j) and immunohistochemistry (IHC) (Fig. S1g, i) also confirmed the amelioration of fibrotic state in lung tissue from Tet treatment group, when compared to untreated silicosis counterparts. Hydroxyproline assay also showed that high-dose Tet dramatically reduced the collagen deposited in silicosis mice (Fig. 1o). Taken together, these results showed that Tet treatment resulted in a dose-dependent reduction in pulmonary inflammation and fibrosis symptoms, as well as lung function impairment in silicosis mouse model.

Late Tet therapeutic treatment reduced inflammation and fibrosis and partially ameliorated impaired lung function in silicosis mice. We next investigated the late therapeutic effects of Tet administration after the formation of silicotic nodules in silicosis mouse by evaluating cardiopulmonary function, inflammation, and fibrosis. Considering the former result, we decided to select the high dose of Tet (100 mg/kg) with better efficacy in this late therapeutic administration model. To this end, we treated C57BL/6J mice with Tet for 4 weeks starting at day 14 after silica exposure (Fig. 2a). We first measured right ventricular function through RVHI (Fig. 2b), RVSP (Fig. 2c, S2a), which revealed that late Tet treatment could lead to decreased RVSP and RVHI. In addition, Tet upregulated Cst (Fig. 2d) significantly and improved Crs (Fig. S2e) and IC (Fig. S2b) in an increasing trend with no significance. Tet down-regulated Rrs (Fig. S2f) significantly, whereas decreased G (Fig. S2c) and H (Fig. S2d) in a trend with no significance in Tet-administered silicosis mice. Collectively, these data suggest that Tet has limited improved effects on cardiopulmonary function when administered after onset in silicosis mice.

We also examined levels of pulmonary inflammation in murine lungs treated with Tet at 2 weeks after silica induction. HE staining (Fig. 2e) and subsequent quantitative image analysis of alveolitis showed higher Szapiel scores (Fig. S2g) induced by silica and mitigation of this effect in the Tet treatment group. We also assessed the transcriptional expression of IL-1β, IL-6, which are inflammatory cytokines commonly used as markers for inflammatory response. In agreement with Szapiel scores, we found that both mRNA levels (Fig. 2f) and protein concentration (Fig. 2g) of IL-1β and IL-6 were all increased in silicosis mice, but were decreased in that of the Tet-treated silicosis mice. The levels of macrophage (Fig. 2h), neutrophil (Fig. S2h), lymphocyte (Fig. S2i) and total cell (Fig. S2j) count in BALF were also decreased by Tet treatment. In addition, we also determined the anti-fibrotic effects of Tet treatment at 2 weeks after the onset of silicotic nodules using hydroxyproline assays (Fig. 2i), Masson’s trichrome staining (Fig. 2j, S2k), and IHC staining of collagen-I (Fig. 2l, S2l), which all showed a substantial reduction in these markers with Tet administration, compared with untreated silicosis mice. In addition, reduced collagen-I and fibronectin-1 mRNA levels (Fig. 2k) and fibronectin-1 protein levels (Fig. S2m) were consistent with the above results. Cumulatively, these experimental results demonstrated that lung inflammation and fibrosis could be substantially attenuated by Tet administration, while cardiopulmonary function could be partially improved in silicosis mouse lungs.

Tet suppressed NLRP3 inflammasome activation induced by silica in vivo
Despite the apparently ameliorative effects of Tet administration observed in silicosis mice, understanding of its mechanism of action remains limited. Hence, we performed RNA sequencing (RNAseq) followed by hierarchical clustering of samples and estimation of differentially expressed genes (DEGs) among lungs of the Si, Si + Tet and PBS mice groups of late administration models (Fig. 3a). The RNAseq analysis revealed that the cytokine, chemokine, Th17, and NOD-like receptor signaling pathways, among others that were the top 30 aberrent pathways contributing to the development of silicosis, were significantly affected by Tet treatment (Fig. 3b). Among these, NLRP3 inflammasome activation that is part of the NOD-like receptor signaling pathway has been reported to participate in the pathogenesis of silicosis [22]. We therefore hypothesized that the therapeutic anti-silicosis effects of Tet may be mediated by inhibiting the activation of NLRP3 inflammasome. To explore this possibility, we used real-time quantitative PCR (qPCR) to detect the relative expression of several essential genes in the NLRP3 inflammasome pathway including NLRP3, ASC, and Caspase-1 (Fig. 3c-e) and Western blots to determine the levels of protein accumulation (Fig. 3g, h) in lung tissue from late administration mouse models, which indicated that the strong activation of NLRP3 inflammasome was repressed by Tet in silicosis mice, although no significant change in ASC mRNA and protein levels was observed. Moreover, mRNA level of IL-1β (Fig. 2f) and concentration in BALF (Fig. 2g) and serum (Fig. 3i) were down-regulated by Tet administration. Similar results were observed in IL-18 at both mRNA (Fig. 3f) and protein levels (Fig. 3j, k). These results strongly suggested that Tet administration inhibited the activation of NLRP3 inflammasome induced by silica exposure in vivo.

Tet inhibited NLRP3 inflammasome activation by canonical and non-canonical pathways in vivo
NLRP3 inflammasome activation is mediated by both canonical and non-canonical signaling pathways. The canonical pathway is co-stimulated by priming and activating signal cascades. The priming signal triggers the TLR4 (Toll-like receptor 4) signaling pathway to initiate the production of precursors such as IL-1β and IL-18; the activating signal prompts the assembly of the NLRP3/ASC/Pro-Caspase-1 protein complex [23]. By contrast, non-canonical NLRP3 inflammasome activation is mediated by Caspase-11 in mice and Caspase-4 and Caspase-5 in human [24]. In our study, we conducted quantitative inflammatory microarray analysis in serum between PBS and silica groups (Fig. 4a) as well as between Silica and Silica + Tet groups (Fig. 4b), combined with whole transcriptome RNAseq in PBS, Silica, and Silica + Tet groups (Fig. 4c) to identify which pathways mediate NLRP3 inflammasome activation in silicosis mice. Intersection in Venn diagram is shown for the enriched pathways by multi-omics analyses (Fig. 4d), containing Toll-like receptor (TLR) signaling pathway, chemokine, cytokine-cytokine receptor interaction and so on (Fig. 4e). Previous reports that the pro-forms of NLRP3 inflammasome associated cytokines were typically generated
through downstream transcriptional regulation of TLR expressions, combined with Venn diagram analysis, suggested that Tet interfered with the Toll-like receptor signaling pathway to inhibit NLRP3 inflammasome activation. We verified this possibility by detecting mRNA (Fig. 4f, g) and protein (Fig. 4i, j) levels of several essential gene factors in the TLR4-MyD88 pathway and found that these markers in silicosis mice declined under Tet treatment. Surprisingly, in addition to blocking the priming step, we observed that Tet treatment could also suppress the canonical activating process mediated by Caspase-1 (Fig. 3e, g, h). Furthermore, we found that Tet reduced mRNA and protein levels of Caspase-11 (Fig. 4h–j), indicating that it also blocked the non-canonical NLRP3 inflammasome activation pathway. Collectively, these results showed that both the canonical and non-canonical pathways of NLRP3 inflammasomes in silicosis were blocked by Tet administration, indicating that its effects in ameliorating silicosis were likely due to suppressing upstream of canonical and non-canonical NLRP3 inflammasome signaling.

Tet restrained NLRP3 inflammasome activation in macrophages According to single cell RNAseq analysis from control and silicosis murine lung tissue, it revealed that NLRP3 expression is mainly restricted to macrophages among 18 different cell populations (Fig. 5a, b). Hence, we proposed that suppression of NLRP3 inflammasomes contributed to the anti-silicosis effects of Tet that mainly occurred in macrophages. We first examined the mRNA (Fig. 5c, d) and protein (Fig. 5i, j) levels of canonical pathway priming genes and found that they were downregulated under Tet treatment in primary macrophages exposed to silica, suggesting that Tet inhibited the regulatory effects of TLR4 and MyD88 in these cells. In addition, Caspase-1 and NLRP3 mRNA (Fig. 5e, f) and protein (Fig. 5i–k) levels in the canonical activating step were consistent with the transcriptional down-regulation observed in the priming step. However, surprisingly, we found that ASC mRNA (Fig. 5g) and protein (Fig. 5i, j) levels were unaltered in both Tet-treated and untreated silicosis mice compared to non-silicosis controls. Non-canonical pathway
Mediated by Caspase-11 was also determined by qPCR (Fig. 5h) and Western blots (Fig. 5i, l) and the results showed that Caspase-11 is down-regulated by Tet treatment in silicosis macrophages. Moreover, the characteristic up-regulation in IL-1β and IL-18 (Fig. 5m) in inflammatory cytokines associated with silicosis was also substantially mitigated in macrophages under Tet treatment. In summary, we confirmed a novel mechanism by which Tet acts in macrophages to suppress NLRP3 inflammasome activation via canonical and non-canonical signaling pathways both in vitro and in vivo, which results in attenuation of pulmonary inflammation and subsequent fibrosis.

DISCUSSION
In this study, we used multiple methods to investigate the efficacy of Tet in both early and late therapeutic administration models of silicosis mice, which resulted in functional, pathological, and molecular level improvements of lung. Using multi-omics techniques, further investigation provided the first evidence that pharmacological repression of NLRP3 inflammasome activation by Tet was likely responsible for the positive treatment outcomes. Taken together, our work lends strong evidence supporting the benefits of Tet in limiting inflammatory conditions accompanying silicosis and provides valuable insights into the mechanisms underlying this disease attenuation.

Tet, a plant-based extract of Stephania tetrandra S. Moore, has already been approved for and applied in clinical treatment of silicosis [4, 8]. In fact, to date, albeit with unclear mechanisms underlying the attenuation of silicosis, this drug remains the only pharmacological treatment for silicosis approved by the National Medical Products Administration. Intriguingly, several clinical trials have reported that patients with Tet treatment have exhibited smaller silicotic nodules under X-ray, and have down-regulated inflammatory cytokines and improved lung function compared to...
their non-Tet treatment counterparts [6]. Our work supports these findings and further confirms that both early and late application of Tet shows favorable outcomes indicating that Tet could dampen silicosis-related inflammation and halt diffuse fibrosis in an experimental mouse model.

Although Tet has previously been reported to be effective in both experimental models and silicotic patients and has a decades-long record of clinical application in China, it has still not been systematically and rigorously investigated as an effective agent for silicosis treatment. In fact, the mechanism by which Tet attenuates silicosis has eluded researchers for several decades, although generally the inhibition of pathological collagen-associated gene expression and inactivation of inflammatory effector cells have been attributed to the Tet-mediated attenuation of silicosis in animal models [6, 25, 26]. However, the specific aberrant factors or pathways that Tet targets remain unclear. NLRP3 inflammasomes in macrophages are essential for silica recognition and initiated subsequent profibrotic events that have been implicated in the pathogenesis of silicosis. Alveolar macrophages are in continuous interaction with the inhaled silica particulates during their clearance, which results in robust release of IL-1β, in an NLRP3 inflammasome-dependent manner [10, 22]. Substantial evidence supports that macrophages stimulated with silica exhibit high levels of IL-1β and that silica-induced fibrosis does not develop in
IL-1R-deficient silicosis mice [27, 28]. Likewise, mice with ASC or NLRP3 knockout are more resistant to developing silica-induced chronic fibrosis. In addition, macrophages lacking these NLRP3 inflammasome components are incapable of releasing proinflammatory IL-1β [22]. In light of previous findings that Tet showed high affinity binding to alveolar macrophages and strongly inhibited production of IL-1β in macrophages [29, 30], we thus speculated that the attenuation of silicosis by Tet might be ascribed to upstream blockade or inhibition of IL-1β and/or NLRP3 inflammasome.

In this study, our work showed that Tet could inhibit both canonical and non-canonical NLRP3 inflammasome pathways, suggesting that Tet likely targets a shared upstream component (or components) (Fig. 5). However, the specific aberrant protein or factor that Tet targets remains unclear. Recently, Peeters et al. reported that particle uptake was pivotal to silica-induced inflammasome activation [30]. Also, they showed that cytochalasin D, an inhibitor that specifically blocks actin polymerization, dramatically attenuated the silica-induced secretion of cytokines by NLRP3 inflammasome activation. These findings indicated that...
cytoskeleton-mediated silica internalization is indispensable for NLRP3 inflammasome activation. Most strikingly, several studies consistently determined that Tet exhibited cytoskeletal depolymerization activity. For example, Chen et al. reported that Tet moderately interrupted the process of collagen biosynthesis by hindering the movement of cytoskeleton to eliminate intracellular procollagen [31, 32]. Lv et al. also found that Tet inhibited the migration and invasion of rheumatoid arthritis fibroblast-like synoviocytes through down-regulation of the key signaling nexus of cytoskeleton formation [33]. In light of these previous studies, we hypothesized that Tet may serve as an initial blocker to prevent silica particle internalization, thus resulting in extensive inhibition of several NLRP3 inflammasome pathway components. In addition, a very recent study also determined that Tet attenuated cerebral ischemia/reperfusion injury by inhibiting NLRP3 via Sirt-1, which silenced many key genes involved in this NLRP3 pathway [34]. These findings indicated that even if the silica particles were internalized by macrophages, Tet could still prevent the activation of NLRP3 by silencing key genes. Further investigations of the specific mechanisms by which Tet regulates the cytoskeleton and Sirt-1 are necessary to definitively understand its targets in silicosis.

In this study, we confirmed the anti-inflammatory and anti-fibrotic effects of Tet based on multiple lines of evidence, including single cell and whole lung RNAseq, quantitative inflammatory microarray of serum and multiple treatments in murine models of silicosis. However, further rigorous and statistically sound confirmation of the clinical benefits of Tet in silicosis patients could require large-scale, longitudinal cohort clinical trials. In addition, mice deficient in components of the NLRP3 pathways are also essential to identify with certainty whether the effects of Tet treatment are dependent on the inactivation of NLRP3 inflammasomes.

CONCLUSION

Using early and late administration strategies, our work demonstrated that Tet can effectively attenuate silica-induced pulmonary inflammation, fibrosis, and impairment of lung function in mice. In addition, based on multiple transcriptomics approaches, we provide the first report of Tet-mediated alleviation of silicosis via inhibition of NLRP3 inflammasome pathway signaling. The results of our study provide a substantial conceptual framework for understanding the basic mechanisms by which Tet ameliorates silicosis. Furthermore, our work also provides strong evidence for clinical strategies that combine Tet with NLRP3 inflammasome pathway inhibitors to increase the efficacy and therapeutic range available for silicosis patients.

ACKNOWLEDGEMENTS

This program was fund by Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (CIFMS) (grant number: 2018-12M-1-001), the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (grant number:2019RC330001) and National Natural Science Foundation of China (grant number: 82009010).

AUTHOR CONTRIBUTIONS

JW, XRZ, and CW designed and supervised this study. MYS and JXW wrote and revised the manuscript with contribution from all authors. PRY reviewed the manuscript. MYS and YL, and BCL constructed the murine silicosis models and carried out the Tet treatment experiment. MYS, Ying Liu, THF, ZGL, XMQ, and Ya Luo contributed to harvesting animals and lung functional test. MYS, JXW, YL, and BCL constructed the murine silicosis models. How ever, further rigorous and statistically sound confirmation of the clinical bene fi ts of Tet in silicosis patients requires large-scale, longitudinal cohort clinical trials. In addition, mice de fi cient in components of the NLRP3 pathways are also essential to identify whether the effects of Tet treatment are dependent on the inactivation of NLRP3 inflammasomes.

REFERENCES

1. Leung CC, Yu ITS, Chen W. Silicosis. Lancet. 2012;379:2008–18.
2. Barnes H, Goh NSL, Leong TL, Hoy R. Silica-associated lung disease: an old-world exposure in modern industries. Respirilo. 2019;24:1165–75.
3. Hoy R, Chambers DC. Silicosis: an ancient disease in need of a dose of modern medicine. Respirolo. 2020;25:464–5.
4. Bhagya N, Chandra谢ker KN. Tetrandrine–a molecule of wide bioactivity. Phytochemistry. 2016;125:5–13.
5. Sun J, Song P, Wang Y, Chen Y. Clinical efficacy of acetylcyesteine combined with tetrandrine tablets in the treatment of silicosis and the effect on serum IL-6 and TNF-a. Exp Ther Med. 2019;18:3383–8.
6. Xie QM, Tang HF, Chen QJ, Bian RL. Pharmacological actions of tetrandrine in inflammatory pulmonary diseases. Acta Pharmacolo Sin. 2002:23:1107–13.
7. Wang R, Ma TM, Liu F, Gao HQ. Research progress on pharmacological action and clinical application of Stephania Tetrandrae Radix. Zhongguo Zhong Yao Za Zhi. 2017;42:634–9.
8. Banks DE, Cheng YH, Weber SL, Ma J. Strategies for the treatment of pneumocnosis, Occup Med. 1993:8:205–32.
9. Peeters PM, Eurlings IMU, Perkins TN, Wouters EF, Schips RPF, Borm PJA, et al. Silica-induced NLRP3 inflammasome activation in vitro and in rats. Part Fibre Toxicol. 2014;11:58.
10. Dostert C, Pettilli V, Van Bruggen R, Steele C, Moxsman BT, Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science. 2008;320:674–7.
11. Hoffman HM, Wanderer AA. Inflammasome and IL-1-beta-mediated disorders. Curr Allergy Asthma Rep. 2010;10:229–35.
12. Guo J, Gu N, Chen J, Shi T, Zhou Y, Rong Y, et al. Neutralization of interleukin-1 beta attenuates silica-induced lung inflammation and fibrosis in C57BL/6 mice. Arch Toxicol. 2013;87:1963–73.
13. CavaII G, Falanca F, Dinalli CA, Dagna L. Treating pulmonary silicosis by blocking interleukin 1. Am J Respir Crit Care Med. 2015:191:596–8.
14. Wu SJ, Ng TT. Tetrandrine inhibits proinflammatory cytokines, iNOS and COX-2 expression in human monocytes. Biol Pharm Bull. 2007:30:59–62.
15. Cao Z, Song M, Liu Y, Pang J, Li Z, Qi X, et al. A novel pathophysiological classification of silicosis models provides some new insights into the progression of the disease. Ecotoxicol Environ Saf. 2020;202:110834.
16. Serrres FJ, Chetboul V, Tissier R, Carlos Sampedrano C, Gouni V, Nicolle AP, et al. Tetrandrine inhibits NLRP3 pathway in silicosis macrophages. Acta Pharmacologica Sinica (2022) 43:1274 – 1284
17. Serres FJ, Chetboul V, Tissier R, Carlos Sampedrano C, Gouni V, Nicolle AP, et al. Tetrandrine inhibits NLRP3 pathway in silicosis macrophages. Acta Pharmacologica Sinica (2022) 43:1274 – 1284
18. Banks DE, Cheng YH, Weber SL, Ma JK. Strategies for the treatment of pneumoconiosis, Occup Med. 1993:8:205–32.
19. Peeters PM, Eurlings IMU, Perkins TN, Wouters EF, Schips RPF, Borm PJA, et al. Silica-induced NLRP3 inflammasome activation in vitro and in rats. Part Fibre Toxicol. 2014;11:58.
20. Dostert C, Pettilli V, Van Bruggen R, Steele C, Moxsman BT, Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science. 2008;320:674–7.
21. Hoffman HM, Wanderer AA. Inflammasome and IL-1-beta-mediated disorders. Curr Allergy Asthma Rep. 2010;10:229–35.
22. Guo J, Gu N, Chen J, Shi T, Zhou Y, Rong Y, et al. Neutralization of interleukin-1 beta attenuates silica-induced lung inflammation and fibrosis in C57BL/6 mice. Arch Toxicol. 2013;87:1963–73.
23. CavaII G, Falanca F, Dinalli CA, Dagna L. Treating pulmonary silicosis by blocking interleukin 1. Am J Respir Crit Care Med. 2015;191:596–8.
24. Wu SJ, Ng TT. Tetrandrine inhibits proinflammatory cytokines, iNOS and COX-2 expression in human monocytes. Biol Pharm Bull. 2007:30:59–62.
25. Cao Z, Song M, Liu Y, Pang J, Li Z, Qi X, et al. A novel pathophysiological classification of silicosis models provides some new insights into the progression of the disease. Ecotoxicol Environ Saf. 2020;202:110834.
26. Serres FJ, Chetboul V, Tissier R, Carlos Sampedrano C, Gouni V, Nicolle AP, et al. Tetrandrine inhibits NLRP3 pathway in silicosis macrophages. Acta Pharmacologica Sinica (2022) 43:1274 – 1284
19. King EJ. Silicosis. Lect Sci Basis Med. 1952;2:108–14. 20. Barnes H, Goh NSL, Leong TL, Hoy R. Silica-associated lung disease: an old-world exposure in modern industries. Respirilo. 2019;24:1165–75.
21. Hoy R, Chambers DC. Silicosis: an ancient disease in need of a dose of modern medicine. Respirolo. 2020;25:464–5.
22. Bhagya N, Chandra谢ker KN. Tetrandrine–a molecule of wide bioactivity. Phytochemistry. 2016;125:5–13.
23. Chen Y, Song P, Wang Y, Chen Y. Clinical efficacy of acetylcyesteine combined with tetrandrine tablets in the treatment of silicosis and the effect on serum IL-6 and TNF-a. Exp Ther Med. 2019:18:3383–8.
24. Xie QM, Tang HF, Chen QJ, Bian RL. Pharmacological actions of tetrandrine in inflammatory pulmonary diseases. Acta Pharmacolo Sin. 2002:23:1107–13.
25. Wang R, Ma TM, Liu F, Gao HQ. Research progress on pharmacological action and clinical application of Stephania Tetrandrae Radix. Zhongguo Zhong Yao Za Zhi. 2017;42:634–9.
26. Banks DE, Cheng YH, Weber SL, Ma J. Strategies for the treatment of pneumoconiosis, Occup Med. 1993:8:205–32.
28. Srivastava KD, Rom WN, Jagirdar J, Yie TA, Gordon T, Tchou-Wong KM. Crucial role of interleukin-1beta and nitric oxide synthase in silica-induced inflammation and apoptosis in mice. Am J Respir Crit Care Med. 2002;165:527–33.

29. Ma JK, Mo CG, Malanga CJ, Ma JY, Castranova V. Binding of bisbenzylisoquinoline alkaloids to phosphatidylcholine vesicles and alveolar macrophages: relationship between binding affinity and antifibrogenic potential of these drugs. Exp Lung Res. 1991;17:1061–77.

30. Kang JH, Lewis DM, Castranova V, Rojanasakul Y, Banks DE, Ma JY, et al. Inhibitory action of tetrandrine on macrophage production of interleukin-1 (IL-1)-like activity and thymocyte proliferation. Exp Lung Res. 1992;18:715–29.

31. Liu LF, Chen NM, Cai GP, Li ZL, Yang JG, Li YR. Studies on the effect of tetrandrine on microtubules. I. Biochemical observation and electron microscopy. Ecotoxicol Environ Saf. 1988;15:142–8.

32. Chen NM, Liu LF, Cai GP, Yang JG, Li YR. Studies on the effect of tetrandrine on microtubules. II. Observation with immunofluorescence techniques. Ecotoxicol Environ Saf. 1988;15:149–52.

33. Lv Q, Zhu XY, Xia YF, Dai Y, Wei ZF. Tetrandrine inhibits migration and invasion of rheumatoid arthritis fibroblast-like synoviocytes through down-regulating the expressions of Rac1, Cdc42, and RhoA GTPases and activation of the PI3K/Akt and JNK signaling pathways. Chin J Nat Med. 2015;13:831–41.

34. Wang J, Guo M, Ma R, Wu M, Zhang Y. Tetrandrine alleviates cerebral ischemia/reperfusion injury by suppressing NLRP3 inflammasome activation via Sirt-1. PeerJ. 2020;8:e9042.